ApexQubit
closedHarnessing a proprietary technology for discovery of new medicines to treat patients with undruggable diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | $60.0k | Early VC | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| % profit margin | - | 94 % |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
ApexQubit is a biotechnology company focused on discovering new medicines to treat patients with diseases that have been historically undruggable. Utilizing proprietary technology, ApexQubit covers the full cycle of drug discovery, emphasizing RNA-targeted therapeutics. The company operates in the healthcare and pharmaceutical markets, specifically targeting therapy areas such as oncology, cardiovascular, immunology, respiratory, neuroscience, and metabolic diseases. ApexQubit serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around research and development, with revenue generated through partnerships, collaborations, and licensing agreements. ApexQubit's team comprises seasoned scientists and engineers, including renowned experts like Dr. Andris Ambainis, who contribute to the company's innovative approach and technological advancements.
Keywords: RNA-targeted therapeutics, undruggable diseases, proprietary technology, drug discovery, oncology, cardiovascular, immunology, respiratory, neuroscience, metabolic.